Ntbc treatment monitoring in chilean patients with tyrosinemia type 1 and its association with biochemical parameters and liver biomarkers

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Treatment and follow-up in Hereditary Tyrosinemia type 1 (HT-1) patients require comprehensive clinical and dietary management, which involves drug therapy with NTBC and the laboratory monitoring of parameters, including NTBC levels, succinylacetone (SA), amino acids, and various biomarkers of liver and kidney function. Good adherence to treatment and optimal adjustment of the NTBC dose, according to clinical manifestations and laboratory parameters, can prevent severe liver complications such as hepatocarcinogenesis (HCC). We analyzed several laboratory parameters for 15 HT-1 patients over one year of follow-up in a cohort that included long-term NTBC-treated patients (more than 20 years), as well as short-term patients (one year). Based on this analysis, we described the overall adherence by our cohort of 70% adherence to drug and dietary treatment. A positive correlation was found between blood and plasma NTBC concentration with a conversion factor of 2.57. Nonetheless, there was no correlation of the NTBC level with SA levels, αFP, liver biomarkers, and amino acids in paired samples analysis. By separating according to the range of the NTBC concentration, we therefore determined the mean concentration of each biochemical marker, for NTBC ranges above 15–25 µmol/L. SA in urine and αFP showed mean levels within controlled parameters in our group of patients. Future studies analyzing a longer follow-up period, as well as SA determination in the blood, are encouraged to confirm the present findings.

References Powered by Scopus

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione)

257Citations
N/AReaders
Get full text

Recommendations for the management of tyrosinaemia type 1.

174Citations
N/AReaders
Get full text

Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations

169Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Role of Alpha-Fetoprotein (AFP) in Diagnosing Childhood Cancers and Genetic-Related Chronic Diseases

7Citations
N/AReaders
Get full text

Mexican consensus on tyrosinemia type 1

0Citations
N/AReaders
Get full text

Simultaneous succinylacetone-nitisinone measurement in tyrosinemia type I patients and evaluation of the nitisinone therapeutic range

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fuenzalida, K., Leal-Witt, M. J., Guerrero, P., Hamilton, V., Salazar, M. F., Peñaloza, F., … Cornejo, V. (2021). Ntbc treatment monitoring in chilean patients with tyrosinemia type 1 and its association with biochemical parameters and liver biomarkers. Journal of Clinical Medicine, 10(24). https://doi.org/10.3390/jcm10245832

Readers over time

‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

67%

Professor / Associate Prof. 1

17%

Researcher 1

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Pharmacology, Toxicology and Pharmaceut... 2

40%

Immunology and Microbiology 1

20%

Save time finding and organizing research with Mendeley

Sign up for free
0